Earnings Roundup: Biodesix, Co-Diagnostics, PhenomeX, HTG Molecular Dx, Accelerate Dx
The Boulder, Colorado-based cancer diagnostics firm had a net loss of $18.7 million, or $.24 per share, in Q1 2023 compared to a net loss of $15.6 …
The Boulder, Colorado-based cancer diagnostics firm had a net loss of $18.7 million, or $.24 per share, in Q1 2023 compared to a net loss of $15.6 …
Based on recent headline ratings, % of this readership currently trusts the local media, which has an average score of % regionally and is currently trending .